Avacc 10 / EpiVax, Intravacc - LARVOL DELTA

Avacc 10: An intranasal Outer Membrane Vesicle based subunit vaccine for COVID 19 (WVCE 2024) - "Sponsored by: Abera Bioscience Ab; Sponsored by: Orlance, Inc.; Sponsored by: Givax Inc.; Sponsored by: Intravacc; Sponsored by: Hisamitsu Pharmaceuticals; Sponsored by: Transmucosis"

Infectious Disease • Novel Coronavirus Disease

ITV2002: Safety and Efficacy of Intranasal Administration of Avacc 10 Vaccine Against COVID-19 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=40 | Completed | Sponsor: Intravacc B.V. | Active, not recruiting ➔ Completed | Trial primary completion date: Feb 2024 ➔ Aug 2023

Trial completion • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

ITV2002: Safety and Efficacy of Intranasal Administration of Avacc 10 Vaccine Against COVID-19 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=40 | Active, not recruiting | Sponsor: Intravacc B.V. | Recruiting ➔ Active, not recruiting | Trial completion date: Jul 2023 ➔ Mar 2024 | Trial primary completion date: Jun 2023 ➔ Feb 2024

Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

ITV2002: Safety and Efficacy of Intranasal Administration of Avacc 10 Vaccine Against COVID-19 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Intravacc B.V. | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease

ITV2002: Safety and Efficacy of Intranasal Administration of Avacc 10 Vaccine Against COVID-19 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=36 | Not yet recruiting | Sponsor: Intravacc B.V.

New P1 trial • Infectious Disease • Novel Coronavirus Disease

Cristal Therapeutics and Intravacc Announce Strategic Collaboration to Advance Novel Vaccine Platforms (PRNewswire.co.uk) - "Intravacc...and Cristal Therapeutics...announced a strategic collaboration to develop novel vaccine programs against human diseases with the initial candidate targeting COVID-19....Cristal Therapeutics and Intravacc will collaborate with an initial focus on generating a CriVac® vaccine candidate based on the receptor-binding domain of the SARS-CoV-2 spike protein....In addition, Cristal Therapeutics will provide its powerful copper-free click chemistry reagent, CliCr®, for evaluation with Intravacc's proprietary outer membrane vesicles (OMV) technology....Intravacc will also provide access to its proprietary, detoxified LPS technology to enhance immune activation."

Licensing / partnership • Infectious Disease • Novel Coronavirus Disease